CTLA4 and neoplasm: Immunotherapy is currently one of the effective methods for anti-lung cancer tumor therapy, in which immune checkpoint inhibitors (ICIs) mainly exert anti-tumor effects by activating T cells, and currently approved ICIs have drugs targeting CTLA4, PD-1 and PD-L1 (169).